

**AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY
AREV NANOTEC BRANDS INC.)**
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars)

**NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the consolidated interim financial statements; they must be accompanied by a notice indicating that the consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Canadian Institute of Chartered Professional Accountants for a review of interim financial statements by an entity's auditor.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Condensed Consolidated Interim Statements of Financial Position

(Unaudited - Expressed in Canadian dollars)

| | Note | As at September 30, 2021 | As at December 31, 2020 |
|--|----------------|-----------------------------|----------------------------|
| ASSETS | | \$ | \$ |
| Current | | | |
| Cash | | 27,403 | 297,626 |
| Amounts receivable | 5, 13 | 85,063 | 26,441 |
| Inventory | | - | 4,629 |
| Prepaid expenses | | 10,830 | 14,172 |
| Assets held for sale | 7 | - | 515,379 |
| Total Current Assets | | 123,296 | 858,247 |
| Non-Current | | | |
| Property and equipment | 7 | 260,631 | 323,873 |
| Right of use asset | 8, 16 | 59,357 | 94,971 |
| Investment | 6 | 1 | 1 |
| Total Assets | | \$443,285 | \$1,277,092 |
| LIABILITIES | | | |
| Current | | | |
| Accounts payable and accrued interest | 10, 11, 12, 13 | 634,423 | 549,095 |
| Due to related parties | 6, 13 | 154,436 | 633,195 |
| Lease liability | 8 | 37,844 | 47,358 |
| Loan payable | 12, 13 | - | 162,970 |
| Convertible debenture | 11, 13 | 473,408 | 473,408 |
| Total Current Liabilities | | 1,300,111 | 1,866,026 |
| Non-Current | | | |
| Lease liability | 8 | 26,691 | 52,300 |
| Total Liabilities | | 1,326,802 | 1,918,326 |
| SHAREHOLDERS' EQUITY | | | |
| Share capital | 14 | 13,032,366 | 12,045,076 |
| Shares issuable | | 7,500 | 105,100 |
| Share subscriptions receivable | | (8,000) | (12,500) |
| Equity portion of convertible debt | 11 | 49,841 | 49,841 |
| Share-based payment reserve | 14 | 2,565,604 | 2,284,567 |
| Warrant reserve | 14 | 13,400 | - |
| Accumulated other comprehensive income | | 130 | 133 |
| Deficit | | (16,605,381) | (15,113,451) |
| Total Shareholders' Deficit | | (944,540) | (641,234) |
| Non-controlling interest | | 61,023 | - |
| | | (883,517) | (641,234) |
| Total Liabilities and Shareholders' Deficit | | \$443,285 | \$1,277,092 |

Nature of operations and going concern (Note 1)

Commitments (Note 16)

Subsequent events (Note 19)

Approved on behalf of the Board of Directors on November 29, 2021:

| | |
|------------------------------|----------------------------------|
| <i>"Mike Withrow"</i> | <i>"Denby Greenslade"</i> |
| _____ Director | _____ Director |

The accompanying notes are an integral part of the condensed consolidated interim financial statements

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Unaudited - Expressed in Canadian dollars, except number of shares)

| | | Three Months Ended | | Nine months ended | |
|--|--------|---------------------------|--------------------|---------------------------|--------------------|
| | Note | September 30, 2021 | September 30, 2020 | September 30, 2021 | September 30, 2020 |
| | | \$ | \$ | \$ | \$ |
| Revenue | | 26,483 | 48,898 | 113,011 | 136,721 |
| Operating Expenses | | | | | |
| Advertising and marketing | | 5,382 | 1,781 | 27,219 | 3,205 |
| Investor relations | | - | - | 229,000 | - |
| Amortization and depreciation | 7, 8 | 37,066 | 39,944 | 110,894 | 110,931 |
| Licensing fees | 13, 14 | - | - | 49,590 | - |
| Consulting and management fees | 13 | 123,592 | 34,209 | 432,651 | 93,919 |
| Office and administration | | 23,804 | 10,994 | 45,202 | 42,270 |
| Professional fees | 13 | 15,876 | 26,088 | 111,766 | 61,531 |
| Property expenses | | 3,329 | 36,361 | 8,251 | 61,712 |
| Rent and utilities | | 5,757 | 5,233 | 18,518 | 19,266 |
| Research and development | | 11,167 | 14,433 | 164,399 | 194,349 |
| Share-based payments | 13, 14 | - | - | 332,337 | - |
| Transfer agent and regulatory fees | | 4,005 | 24,238 | 24,592 | 47,777 |
| Travel and accommodation | | - | 632 | 3,278 | 2,499 |
| Total Operating Expenses | | 229,978 | 193,913 | 1,557,697 | 642,459 |
| Loss Before Other Expenses | | (203,495) | (145,015) | (1,444,686) | (505,738) |
| Other Income (Expenses) | | | | | |
| Accretion of discount on debenture | | - | - | - | (226) |
| Gain on settlement of debt | 12, 14 | 16,599 | - | 16,629 | - |
| Impairment of inventory | | - | - | (4,629) | - |
| Foreign Exchange | | - | - | (368) | - |
| Forgiveness of debt | 13 | (21,947) | - | (21,947) | - |
| Interest expense | 11, 12 | (11,071) | (13,573) | (36,929) | (40,941) |
| Total Other Income (Expenses) | | (16,419) | (13,573) | (47,244) | (41,167) |
| Net Loss | | (219,914) | (158,588) | (1,491,930) | (546,905) |
| Other Comprehensive Income (Loss) | | | | | |
| Unrealized gain (loss) on foreign currency translation | | 992 | (16) | 2,500 | (125) |
| Total Comprehensive Loss | | \$(218,922) | \$(158,604) | \$(1,489,430) | \$(547,030) |
| Net Loss Attributable To: | | | | | |
| Shareholders | | (219,914) | (158,604) | (1,491,930) | (546,905) |
| Non-controlling interest | | - | - | - | - |
| | | \$(219,914) | \$(158,604) | \$(1,491,930) | \$(546,905) |
| Comprehensive Income (Loss) Attributable To: | | | | | |
| Shareholders | | (219,943) | (158,604) | (1,491,933) | (125) |
| Non-controlling interest | | 1,021 | - | 2,503 | - |
| | | \$(218,922) | \$(158,604) | \$(1,489,430) | \$(125) |
| Loss per share: | | | | | |
| Basic and diluted | | \$(0.01) | \$(0.01) | \$(0.06) | \$(0.04) |
| Weighted average number of shares outstanding: | | | | | |
| Basic and diluted | | 25,433,807 | 17,816,504 | 24,008,410 | 14,481,529 |

The accompanying notes are an integral part of the condensed consolidated interim financial statements

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)
Condensed Consolidated Interim Statements of Changes in Shareholders' Defecit

(Unaudited - Expressed in Canadian Dollars, except number of shares)

| | Share capital | | | | Equity | | | Accumulated | Non- | | |
|---|-------------------|---------------------|-------------------|------------------|-----------------|--------------------|-----------------|---------------|-----------------|-----------------------|--------------------|
| | Common | Amount | Share | Shares | Portion of | Share-based | Warrant | Other | Controlling | Deficit | Total |
| | shares | | Subscription | Issuable | Convertible | Payment | Reserve | Comprehensive | Interest | | |
| | | | Receivable | | Debentures | Reserve | | Income | | | |
| Balance at December 31, 2019 | 9,457,807 | \$11,315,076 | \$(12,500) | \$7,500 | \$49,841 | \$2,178,608 | \$- | \$254 | \$- | \$(14,064,573) | \$(525,794) |
| Shares issued for cash (Note 14) | 7,500,001 | 450,000 | - | - | - | - | - | - | - | - | 450,000 |
| Shares for debt (Note 14) | 1,000,000 | 100,000 | - | - | - | - | - | - | - | - | 100,000 |
| Foreign currency translation loss | - | - | - | - | - | - | - | (125) | - | - | (125) |
| Net Loss | - | - | - | - | - | - | - | - | - | (546,905) | (546,905) |
| Balance at September 30, 2020 | 17,957,808 | \$11,865,076 | \$(12,500) | \$7,500 | \$49,841 | \$2,178,608 | \$- | \$129 | \$- | \$(14,611,478) | \$(522,824) |
| Balance at December 31, 2020 | 20,207,807 | \$12,045,076 | \$(12,500) | \$105,100 | \$49,841 | \$2,284,567 | \$- | \$133 | \$- | \$(15,113,451) | \$(641,234) |
| Shares issued for cash (Note 14) | 3,660,000 | 751,700 | - | (97,600) | - | - | 13,300 | - | - | - | 667,400 |
| Shares for debt (Note 14) | 20,000 | 4,900 | - | - | - | - | 100 | - | - | - | 5,000 |
| Exercise of warrants (Note 14) | 985,000 | 78,800 | - | - | - | - | - | - | - | - | 78,800 |
| Exercise of options (Note 14) | 300,000 | 102,300 | - | - | - | (51,300) | - | - | - | - | 51,000 |
| Share-based payment (Note 14) | 261,000 | 49,590 | - | - | - | - | - | - | - | - | 49,590 |
| Share-based payment – stock options (Note 14) | - | - | - | - | - | 332,337 | - | - | - | - | 332,337 |
| Cash received from prior financing | - | - | 4,500 | - | - | - | - | - | - | - | 4,500 |
| Incorporation of Arev Cambodia | - | - | - | - | - | - | - | - | 58,520 | - | 58,520 |
| Foreign currency translation gain | - | - | - | - | - | - | - | (3) | 2,503 | - | 2,500 |
| Net Loss | - | - | - | - | - | - | - | - | - | (1,489,930) | (1,489,930) |
| Balance at September 30, 2021 | 25,433,807 | \$13,032,366 | \$(8,000) | \$7,500 | \$49,841 | \$2,565,604 | \$13,400 | \$160 | \$61,023 | \$(16,603,381) | \$(883,517) |

The accompanying notes are an integral part of the condensed consolidated interim financial statements

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Condensed Interim Statements of Cash Flows

For the nine months ended September 30, 2021 and September 30, 2020

(Unaudited - Expressed in Canadian dollars)

| | 2021 | 2020 |
|--|--------------------|------------------|
| | \$ | \$ |
| Operating activities | | |
| Net loss for the period | (1,491,930) | (546,905) |
| Adjustments for: | | |
| Amortization and depreciation | 110,894 | 110,931 |
| Accretion of discount on convertible debentures | - | 226 |
| Investment | - | (80,000) |
| Share-based payments | 332,337 | - |
| Finance interest | 36,929 | - |
| Impairment of inventory | 4,629 | - |
| Gain on settlement of debt | (16,629) | - |
| Shares issued for license | 49,590 | - |
| Forgiveness of debt | 21,947 | - |
| Changes in non-cash working capital | | |
| Amounts receivable | (20,567) | (17,001) |
| Prepaid expenses and deposits | 3,342 | 18,986 |
| Accounts payable and accrued interest | 75,122 | 137,759 |
| Due to related parties | (478,759) | 94,663 |
| Net cash flows used in operating activities | (1,373,095) | (281,341) |
| Investing activities | | |
| Purchase of property and equipment | (12,038) | (145,340) |
| Lease payments on right-of-use asset | (40,217) | (35,123) |
| Proceeds from sale of property | 515,379 | - |
| Net cash flows provided by (used in) investing activities | 463,124 | (180,463) |
| Financing activities | | |
| Proceeds from issuance of common shares | 667,400 | 450,000 |
| Proceeds from exercise of warrants | 51,000 | - |
| Proceeds from exercise of options | 78,800 | - |
| Repayment of loans | (162,970) | - |
| Funds received from prior financing | 4,500 | - |
| Net cash flows provided by financing activities | 638,730 | 450,000 |
| Effects of foreign exchange on rate changes on cash | 1,018 | - |
| Change in cash | (270,223) | (12,019) |
| Cash, beginning of year | 297,626 | 29,681 |
| Cash, end of year | \$27,403 | \$17,662 |

Supplemental cash flow information (Note 15)

The accompanying notes are an integral part of the condensed consolidated interim financial statements

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Notes to the Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

1. NATURE OF OPERATIONS AND GOING CONCERN

AREV Life Sciences Global Corp. (formerly AREV Nanotec Brands Inc.) (the “Company”) was incorporated under the Business Corporations Act (Alberta) on November 22, 2005. The Company is a fully integrated, early-stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. The Company’s strategy is dedicated to generating revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities.

On March 19, 2020, the Company consolidated its share capital on a 6-for-1 basis. These condensed consolidated interim statements reflect this share consolidation on a retroactive basis.

On May 22, 2021, the Company incorporated Arev (Cambodia) Brands Co., Ltd. (“Arev Cambodia”) based in Cambodia. Arev Cambodia is a 51% owned subsidiary of the Company.

The registered address of the Company is Suite 440, 890 West Pender Street, Vancouver, BC, V6C 1J9. The principal place of business of the Company is 109 - 91 Golden Drive, Coquitlam, BC, V3K 6R2. The Company is listed on the Canadian Securities Exchange (“CSE”) under the symbol “AREV” and on October 9, 2019, the common shares began trading on the OTCQB Market (“OTCQB”) under the symbol “AREVF”.

These condensed consolidated interim financial statements (the “financial statements”) have been prepared on a going concern basis, which assumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company incurred a net loss of \$1,491,930 during the period ended September 30, 2021 and has an accumulated deficit as at September 30, 2021 of \$16,603,381. Further, the Company has no source of operating cash flows, and there is no assurance that sufficient funding (including adequate financing) will be available to conduct required development work. These factors indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern.

The application of the going concern concept is dependent upon the Company’s ability to generate future profitable operations and receive continued financial support from its creditors and shareholders. These financial statements do not give effect to any adjustments that might be required should the Company be unable to continue as a going concern. These adjustments could be material.

In 2020, there was a global outbreak of coronavirus that has resulted in changes in global supply and demand of certain mineral and energy products. These changes, including a potential economic downturn and any potential resulting direct and indirect negative impact to the Company cannot be determined, but they could have a prospective material impact to the Company’s project exploration activities, cash flows and liquidity.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Notes to the Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

2. BASIS OF PRESENTATION

a) Statement of compliance

These interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standard 34 - Interim Financial Reporting, using accounting policies consistent with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board. IFRS includes International Accounting Standards (“IAS”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). As such, these interim financial statements do not contain all the disclosures required by IFRS for annual financial statements and should be read in conjunction with the Company’s audited annual consolidated financial statements for the year ended December 31, 2020.

These financial statements were approved and authorized for issuance by the Company’s Board of Directors on November 29, 2021.

b) Basis of measurement

These interim financial statements have been prepared on a historical cost basis, except for those financial instruments which have been classified and measured at fair value. In addition, with the exception of cash flow information, these financial statements have been prepared using the accrual method of accounting.

All amounts in these financial statements are presented in Canadian dollars, the functional currency of the Company. The accounting policies set out below have been applied consistently.

c) Functional and presentation currency

Each entity within the Company has its results measured using the primary economic environment in which the entity operates. Judgment is necessary in assessing each entity’s functional currency. The Company considers the primary and secondary indicators as part of its decision-making process. The condensed consolidated interim financial statements are presented in Canadian dollars, which is also the functional currency of the Company. The functional currency of Arev Cambodia is the Riel.

d) Basis of consolidation

These condensed consolidated interim financial statement have been prepared on a consolidated basis and include the account of the Company and the following subsidiaries:

| Entity | Registered | Holding |
|---|-------------------|----------------|
| Deutsche Medizinal Cannabis UG (inactive) | Munich, Germany | 100% |
| Arev (Cambodia) Brands Co., Ltd. | Cambodia | 51% |

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Company's audited consolidated financial statements for the year ended December 31, 2020. The audited annual consolidated financial statements are available on SEDAR at www.sedar.com. These policies have been applied throughout the periods reported.

4. MAIN SOURCE OF ESTIMATION UNCERTAINTY AND CRITICAL JUDGEMENTS BY MANAGEMENT

The preparation of condensed consolidated interim financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities as at the date of the condensed consolidated interim financial statements and the reported amount of revenues and expenses for the reporting period.

The main sources of estimation uncertainty and critical judgments by management applicable to these condensed consolidated interim financial statements are the same as those presented in the Company's consolidated financial statements for the year ended December 31, 2020.

5. AMOUNTS RECEIVABLE

| | September 30, 2021 | December 31, 2020 |
|---------------------------------------|---------------------------|--------------------------|
| | \$ | \$ |
| GST receivable | 20,382 | 22,914 |
| Due from related party ⁽¹⁾ | 61,023 | - |
| Miscellaneous | 3,658 | 3,527 |
| | \$85,063 | \$26,441 |

(1) Due from related party relates to a receivable recorded in Arev Cambodia for the 49% interest in the subsidiary. As at September 30, 2021 196,000,000 Riel (\$61,023) (2020 - \$Nil) was due from the shareholder holding 49% interest in the subsidiary.

6. JOINT VENTURE

On June 18, 2020, the Company entered into a Joint Venture Agreement with Absolem Mushroom Extraction Inc. ("Absolem"). The goal of the joint venture is to develop a series of proprietary extraction procedures on a broad variety of fungi production what might be considered to be mushrooms of a "medicinal nature". As at September 30, 2021, the Joint Venture has not been formed.

Upon formation of the joint venture the Company will have a 50% interest in the joint venture in return for providing Absolem with use of the equipment and providing its expertise, knowledge, knowhow, research methods, scientific facilities and personnel. Absolem contributed \$20,000 cash and issued 1,066,667 common shares of Absolem to the Company, valued at \$80,000, in addition to providing supplies of mushrooms for research purposes of the joint venture. The common shares of Absolem are subject to share resale restrictions (i) no sales prior to a date that is 4 months after the distribution date or the date that Absolem becomes a reporting issuer in Canada, and (ii) without Absolem's consent the shares are released over a 36 month period following the listing of Absolem's securities on a Canadian stock exchange.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

6. JOINT VENTURE

The 1,066,667 common shares of issued to the Company have been impaired by \$79,999, to \$1 as at December 31, 2020.

As at September 30, 2021, the Company owes \$100,000 to this joint venture.

7. PROPERTY AND EQUIPMENT

| | Land | Equipment | Leasehold Improvements | Total |
|--|----------------|------------------|-----------------------------------|------------------|
| Cost | \$ | \$ | \$ | \$ |
| Balance, December 31, 2019 | 572,300 | 287,113 | 3,200 | 862,613 |
| Additions | - | 145,340 | - | 145,340 |
| Reclassification of assets held for sale | (572,300) | - | - | (572,300) |
| Impairment | - | (104,667) | - | (104,667) |
| Balance December 31, 2020 | - | 490,602 | 3,200 | 493,802 |
| Additions | - | 12,038 | - | 12,038 |
| Balance September 30, 2021 | \$- | \$502,640 | \$3,200 | \$505,840 |
| Accumulated Depreciation | \$ | \$ | \$ | \$ |
| Balance, December 31, 2019 | - | 65,560 | 3,200 | 68,760 |
| Additions | - | 101,169 | - | 101,169 |
| Balance December 31, 2020 | - | 166,729 | 3,200 | 169,929 |
| Additions | - | 75,280 | - | 75,280 |
| Balance September 30, 2021 | \$- | \$242,009 | \$3,200 | \$245,209 |
| Carrying Value | | | | |
| As at December 31, 2020 | \$- | \$323,873 | \$- | \$323,873 |
| As at September 30, 2021 | \$- | \$260,631 | \$- | \$260,631 |

Land held for sale is the Company's interest in a property in Sorrento, BC. The property which was listed for sale as at December 31, 2020. The sale of the land closed on March 29, 2021 for net proceeds of \$515,165. As at December 31, 2020 a loss on revaluation of assets held for sales of \$56,921 was recognized.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

8. LEASES

The following tables summarize the difference between the operating lease commitment disclosed immediately preceding the date of recognition and the lease liability recognized in the condensed consolidated statement of financial position:

| Right of Use Asset | \$ |
|------------------------------------|-----------------|
| Balance, December 31, 2019 | - |
| Additions | 142,455 |
| Amortization | (47,484) |
| Balance, December 31, 2020 | 94,971 |
| Amortization | (35,614) |
| Balance, September 30, 2021 | \$59,357 |
| Lease Liability | \$ |
| Balance, December 31, 2019 | - |
| Additions | 142,455 |
| Lease payment | (52,650) |
| Lease interest | 9,853 |
| Balance, December 31, 2020 | 99,658 |
| Lease payment | (40,217) |
| Lease interest | 5,094 |
| Balance, September 30, 2021 | \$64,535 |
| | \$ |
| Current portion | 37,844 |
| Long-term portion | 26,691 |
| Balance, September 30, 2021 | \$64,535 |

9. INTANGIBLES

On April 4, 2020, the Company entered into an asset purchase agreement with a company controlled by the Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to purchase a flash freezing extraction apparatus, the method, engineering know-how, business models and trade secrets consideration for \$200,000. Of the \$200,000 purchase price \$104,667 was allocated to the equipment (Note 6) and \$95,333 was allocated to the intangible assets. As at December 31, 2020 a loss on impairment of the equipment and the intangible assets was recognized to write-down the equipment and Intangible assets to \$nil and as such no balance remains on the consolidated interim statement of financial position as at September 30, 2021.

10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

| | September 30, 2021 | December 31, 2020 |
|--------------------------|---------------------------|--------------------------|
| | \$ | \$ |
| Trade payables | 760,581 | 432,942 |
| Accrued interest payable | 126,158 | 116,153 |
| | \$634,423 | \$549,095 |

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

11. CONVERTIBLE DEBENTURES

On July 3, 2018, the Company issued a \$450,000 convertible debenture related to the asset purchase and sale agreement with Matthew Harvey carrying on business under the branding “BC Bud Depot”. The debenture accrues interest at 8% per annum, was due on July 3, 2019, and is convertible into common shares of the Company at a price of \$3.00 per common share. As at September 30, 2021, the accrued interest on the debenture totaled \$115,792 (December 31, 2020 - \$89,753). This interest is included in the accounts payable and accrued interest (Note 10). On January 29, 2020, the Company filed a lawsuit against Matthew Harvey for non-delivery of assets and is claiming that \$5,250,000 paid for the assets by the issuance of shares of the Company. The lawsuit was filed in the Supreme Court of BC. With the exception of this debenture and its accrued interest, no additional assets or liabilities have been included in these financial statements as the outcome of the litigation cannot be reasonably determined at this time (Note 16).

On January 17, 2019, the Company closed a purchase and sale agreement to acquire a 100% interest in real estate located in Sorrento, B.C. from a company controlled by the Chief Executive Officer of the Company. The purchase price was \$572,300 of which \$23,408 was paid by way of a convertible debenture issued by the Company accruing interest at 8% per annum. The remaining balance was paid in cash, of which \$526,592 was paid in fiscal 2018 and the remaining \$22,300 paid in fiscal 2019. The outstanding principal amount and outstanding accruing interest of the convertible debenture is convertible into common shares of the Company at a price of \$1.80 per common share. As at September 30, 2021, the accrued interest on the debenture totaled \$10,366 (December 31, 2020 - \$7,554) and is included in accounts payable and accrued liabilities. (Note 10).

12. LOANS

On March 5, 2019, the Company borrowed \$100,000 from an arm’s length party which bears interest at 8% compounded annually, is unsecured by a specific fixed asset and due on demand. On March 25, 2021 the Company repaid the principal balance of \$100,000 and upon repayment the lender forgave the \$16,597 of accrued interest during the period ended September 30, 2021. As at September 30, 2021 accrued interest of \$nil (December 31, 2020 - \$14,597) is included in accounts payable and accrued liabilities (Note 10).

On January 17, 2019, the Company acquired land which had a mortgage retained on title in the amount of \$62,970. The mortgage is non-interest bearing is subject to repayment upon the Company disposing of the land. On March 23, 2021, the Company repaid the balance and as at September 30, 2021 \$Nil (December 31, 2020 - \$62,970) remains outstanding.

13. RELATED PARTY TRANSACTIONS

During the period ended September 30, 2021, the Company incurred:

- \$2,812 (2020 - \$2,907) in interest expense to a Company related to the CEO of the Company.
- \$18,146 (2020 - \$nil) in share-based payments in connection to 100,000 options (2020 – nil) granted to a director of the Company.
- \$54,000 (2020 - \$54,000) in consulting fees to the Corporate Secretary of the Company.
- \$30,041 (2020 - \$nil) in professional fees to a former Director of the Company
- \$58,746 (2020 - \$5,269) in consulting fees to the CFO of the Company
- \$49,590 (2020 - \$nil) for licensing fees to a company controlled by a Director of the Company

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Notes to the Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

13. RELATED PARTY TRANSACTIONS (continued)

- Recognized a loss of \$21,947 for the forgiveness of debt due from a company controlled by the CEO of the Company.

As at September 30, 2021 the Company owed:

- \$33,774 (December 31, 2020 - \$220,331) to a company controlled by the CEO of the Company. The amount consists of a payable of \$nil due from a company controlled by the CEO (December 31, 2020 – payable of \$189,369) which is non-interest bearing, unsecured and due on demand, and \$23,408 (December 31, 2020 - \$23,408) plus accrued interest of \$10,366 (December 31, 2020 - \$7,554) from a convertible debenture (Note 11).
- \$76,971 (December 31, 2020 - \$63,000), of which \$22,535 (December 31, 2020 - \$Nil) was recorded in accounts payable and \$54,436 (December 31, 2020 - \$101,561) is recorded in due to related parties, to the Corporate Secretary of the Company.
- \$28,996 (December 31, 2020 - \$nil) to a former Director of the Company
- \$100,000 (December 31, 2020 - \$100,000) to a joint venture to be formed with Absolem which is recorded in due to related parties.
- \$17,654 (December 31, 2020 - \$10,333) to the CFO of the Company

As at September 30, 2021 196,000,000 Riel (\$61,023) (December 31, 2020 - \$Nil) was due from the shareholder holding 49% interest in the subsidiary for the purchase of 49% interest in the subsidiary.

14. SHARE CAPITAL

The Company is authorized to issue an unlimited number of common shares without par value, 20,000,000 preferred shares, issuable in one or more series, and 20,000,000 redeemable preferred shares, issuable in one or more series.

Share transactions

During the nine months ended September 30, 2021, the Company issued the following:

- a) On January 6, 2021, the Company issued 1,000,000 units at \$0.10 per unit for proceeds of \$100,000. Each unit consists of one common share and one share purchase warrant with each warrant being exercisable at \$0.15 for a period of 12 months.
- b) On January 4, 2021 485,000 warrants were exercised at a price of \$0.08 per share for total proceeds of \$38,800
- c) On March 16, 2021, 100,000 options were exercised at a price of \$0.17 per share for total proceeds of \$17,000. Upon exercise \$17,100 was reallocated from share-based payment reserve to share capital.
- d) On March 24, 2021, 200,000 options were exercised at a price of \$0.17 per share for total proceeds of \$34,000. Upon exercise \$34,200 was reallocated from share-based payment reserve to share capital.
- e) On March 31, 2021, the Company issued 2,680,000 units at \$0.25 per unit for proceeds of \$665,000. The Company had issued 20,000 shares to settle \$5,000 of debt owed to a consultant of the Company, no gain or loss was recognized on settlement. Based on the residual valuation method a value of \$13,400 was assigned to the warrants granted which was recognized as warrant reserve.
- f) On June 3, 2021, the Company issued 261,000 with a fair value of \$49,590 in connection to the distribution agreement signed with Germinator Genesis to obtain license rights.
- g) On June 8, 2021, 500,000 warrants were exercised at a price of \$0.08 per share for total proceeds of \$40,000

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

14. SHARE CAPITAL (continued)**Share transactions (continued)**

During the year ended December 31, 2020, the Company issued the following:

- a) On April 3, 2020, the Company issued 3,750,000 units at \$0.06 per unit for proceeds of \$225,000. Each unit was comprised of one common share and one share purchase with each warrant being exercisable at \$0.08 per share expiring two years from the date of issuance.
- b) On April 17, 2020, the Company issued 3,750,000 units at \$0.06 per unit for proceeds of \$225,000. Each unit was comprised of one common share and one share purchase warrant with each warrant being exercisable at \$0.08 per share expiring two years from the date of issuance.
- c) On July 13, 2020, the Company settled \$100,000 in debt with the CEO of the Company by the issuance of 1,000,000 common shares at \$0.10.
- d) On December 22, 2020, the Company received share subscription proceeds in advance of \$97,600.
- e) On December 31, 2020, 2,250,000 warrants were exercised at a price of \$0.08 per share for 2,250,000 shares.

Share purchase warrants

Below is a summary of warrant activity during the Nine months ended September 30, 2021:

| | Amount Outstanding | Weighted Average Exercise Price |
|--------------------------------------|-----------------------|------------------------------------|
| | | \$ |
| Outstanding December 31, 2019 | 255,557 | 1.77 |
| Issued | 7,500,000 | 0.08 |
| Exercised | (2,250,000) | 0.08 |
| Expired | (255,557) | 1.77 |
| Balance at December 31, 2020 | 5,250,000 | 0.08 |
| Issued | 3,680,000 | 0.24 |
| Exercised | (985,000) | 0.08 |
| Balance at September 30, 2021 | 7,945,000 | \$0.16 |

Below is a summary of warrants outstanding as at September 30, 2021:

| Warrants Outstanding | Exercise Price (\$) | Expiry Date | Weighted Average Remaining Life (years) |
|-------------------------|---------------------|-----------------|--|
| 1,500,000 | 0.08 | April 3, 2022 | 0.51 |
| 2,765,000 | 0.08 | April 17, 2022 | 0.55 |
| 1,000,000 | 0.15 | January 6, 2022 | 0.27 |
| 2,680,000 | 0.25 | March 31, 2022 | 1.50 |
| 7,945,000 | \$0.16 | | 0.82 |

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

14. SHARE CAPITAL (continued)**Options**

During the Nine months ended September 30, 2021, the Company granted the following options:

- a) On January 14, 2021, 100,000 stock options exercisable at a price of \$0.31 for a period of 5 years. The Company recognized \$30,356 in share-based payments in connection to this grant.
- b) On January 19, 2021, 50,000 stock options exercisable at a price of \$0.31 for a period of 5 years. The Company recognized \$15,672 in share-based payments in connection to this grant.
- c) On February 2, 2021, 50,000 stock options exercisable at a price of \$0.0.275 for a period of 5 years. The Company recognized \$11,981 in share-based payments in connection to this grant.
- d) On February 9, 2021, 250,000 stock options exercisable at a price of \$0.31 for a period of 5 years. The Company recognized \$83,342 in share-based payments in connection to this grant.
- e) On February 17, 2021, 350,000 stock options exercisable at a price of \$0.39 for a period of 5 years. The Company recognized \$109,514 in share-based payments in connection to this grant.
- f) On February 19, 2021, 100,000 stock options exercisable at a price of \$0.305 for a period of 5 years. The Company recognized \$38,314 in share-based payments in connection to this grant.
- g) On June 1, 2021, 150,000 stock options exercisable at a price of \$0.17 for a period of 5 years. The Company recognized \$25,011 in share-based payments in connection to this grant.
- h) On June 10, 2021, 100,000 stock options exercisable at a price of \$0.31 for a period of 5 years. The Company recognized \$18,147 in share-based payments in connection to this grant.

During the year ended December 31, 2020, the Company recorded share-based compensation of \$105,959. The weighted average grant date fair value of stock options granted during the year ended December 31, 2020 was \$0.15 per share.

The fair value for stock options granted have been estimated suing the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions:

| | Nine months ended September 30, 2021 | Year ended December 31, 2020 |
|-------------------------|---|---|
| Risk-free interest rate | 0.61% | 0.44% |
| Expected life (years) | 5 | 5 |
| Expected volatility | 207.5% | 202.7% |

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

14. SHARE CAPITAL (continued)**Options (continued)**

A summary of the Company's stock option activity is as follows:

| | Number Outstanding | Weighted Average Exercise Price |
|--|---------------------------|--|
| | | \$ |
| Balance, December 31, 2019 | 212,500 | 2.19 |
| Granted | 700,000 | 0.16 |
| Cancelled | (112,500) | 2.40 |
| Balance, December 31, 2020 | 800,000 | 0.38 |
| Granted | 1,150,000 | 0.30 |
| Exercised | 300,000 | 0.17 |
| Outstanding at September 30, 2021 | 1,650,000 | 0.37 |

A summary of the Company's stock options outstanding and exercisable as at September 30, 2021 is presented below:

| Expiry Date | Options Outstanding | Options Exercisable | Exercise Price (\$) | Remaining Years |
|--------------------|--------------------------------|--------------------------------|--------------------------------|------------------------|
| December 7, 2022 | 8,333 | 8,333 | 2.940 | 1.19 |
| September 14, 2023 | 33,333 | 33,333 | 2.400 | 1.96 |
| April 25, 2024 | 16,667 | 16,667 | 1.320 | 2.57 |
| May 2, 2024 | 16,667 | 16,667 | 1.950 | 2.59 |
| June 10, 2024 | 8,333 | 8,333 | 1.560 | 2.70 |
| July 16, 2024 | 16,667 | 16,667 | 1.380 | 2.79 |
| December 14, 2025 | 400,000 | 400,000 | 0.150 | 4.21 |
| January 14, 2026 | 100,000 | 100,000 | 0.310 | 4.29 |
| January 19, 2026 | 50,000 | 50,000 | 0.310 | 4.31 |
| February 2, 2026 | 50,000 | 50,000 | 0.275 | 4.35 |
| February 9, 2026 | 250,000 | 250,000 | 0.310 | 4.36 |
| February 17, 2026 | 350,000 | 350,000 | 0.390 | 4.39 |
| February 19, 2026 | 100,000 | 100,000 | 0.305 | 4.39 |
| June 1, 2026 | 150,000 | 150,000 | 0.170 | 4.67 |
| June 10, 2026 | 100,000 | 100,000 | 0.185 | 4.70 |
| | 1,650,000 | 1,650,000 | 0.37 | 4.25 |

15. SUPPLEMENTAL CASH FLOW INFORMATION

| | Nine months ended September 30, 2021 | Nine months ended September 30, 2020 |
|---|---|---|
| | \$ | \$ |
| Non-cash investing and financing activities: | | |
| Shares issued for debt settlement | 5,000 | - |

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)**Notes to the Condensed Consolidated Interim Financial Statements****For the nine months ended September 30, 2021**

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

16. COMMITMENTS AND CONTINGENCIES**Lease Commitments**

On December 2, 2019, the Company entered into an industrial lease agreement until December 2, 2022. The lease commenced on January 2, 2020. Expected annual payments under this lease arrangement are as follows:

| | \$ |
|------|-----------------|
| 2021 | 13,406 |
| 2022 | 54,635 |
| | \$68,041 |

Pending Litigation

On January 29, 2020, the Company commenced litigation in the Supreme Court of British Columbia against the Defendant, Matthew Harvey, the vendor of the BC Bud Depot Assets. The Company is seeking damages, punitive damages, interest, injunctive relief, and costs relating to breach of contract between Matthew Harvey and the Company. The outcome of the litigation cannot be reasonably determined at this time.

On August 17, 2021, the Company was approached by the Ministry of Labour regarding a complaint filed by a former consultant of the Company for unpaid fees relating to services rendered in 2019. As at September 30, 2021 the Company has recorded \$9,019 in relation to the services rendered by the consultant in accounts payable and does not expect to pay any additional damages or fees. However, the outcome of this complaint cannot be reasonably determined at this time.

17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company provides disclosures that enable users to evaluate (a) the significance of financial instruments for the entity's financial position and performance; and (b) the nature and extent of risks arising from financial instruments to which the entity is exposed during the period and at the date of the statement of financial position, and how the entity manages these risks.

The Company provides information about its financial instruments measured at fair value at one of three levels according to the relative reliability of the inputs used to estimate the fair value:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's financial instruments consist of cash, receivables, and accounts. The carrying values of these financial instruments approximate their respective fair values due to the term of these instruments.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Notes to the Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

As at September 30, 2021, the fair value of cash held by the Company was based on level 1 inputs of the fair value hierarchy.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

The Company's primary exposure to credit risk is its cash of \$27,403 at September 30, 2021. With cash on deposit with reputable financial institutions, it is management's opinion that the Company is not exposed to significant credit risks arising from the financial instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. As at September 30, 2021, the Company had current liabilities totaling \$1,300,111 and cash of \$27,403 and is exposed to significant liquidity risk at this time. However, since the Company is in the exploration stage, it will periodically have to raise funds to continue operations and intends to raise further financing through private placements.

Market risk

Market risk is the risk that changes in market prices such as commodity prices, foreign exchange rates and interest rates will affect the Company's income. The objective of market risk management is to manage and control market risk exposure within acceptable parameters. The Company does not use derivative instruments to reduce its insignificant exposure to market risks.

18. CAPITAL MANAGEMENT

The Company includes shareholders' equity and any debt it may issue, in the definition of capital. The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders.

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the acquisition and exploration of mineral properties. The Board of Directors does not establish quantitative return on capital criteria for management but rather relies on the expertise of the Company's management and consultants to sustain future development of the business.

The Company's property is in the exploration stage and as such the Company is dependent upon external financings to fund activities. In order to carry out planned exploration and pay for administrative costs, the Company will spend its existing working capital and raise additional funds required.

Management reviews its capital management approach on an ongoing basis and believes that this approach is reasonable given the relative size of the Company. The Company is not subject to any external covenants.

AREV LIFE SCIENCES GLOBAL CORP. (FORMERLY AREV NANOTEC BRANDS INC.)

Notes to the Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2021

(Unaudited - Expressed in Canadian dollars – unless otherwise noted)

19. SUBSEQUENT EVENTS

On November 8, 2021, the Company granted 700,000 stock options to directors, officers and consultants of the company at a price of 12 cents for a period of five years from the issuance dated. These options will vest immediately.

On November 8, 2021, the Company settled \$10,000 in debt with Chiron Capital Inc., a company wholly owned by a director of the company, by the issuance of 83,333 shares at 12 cents.

On November 19, 2021, the CEO of the Company exercised 1,000,000 warrants at a price of \$0.08 per share for total proceeds of \$80,000.